Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Huperzine A wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Huperzine A and Piracetam have evidence — compare verdict strength side-by-side.
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
1200-4800mg daily in divided doses
Divided into 2-3 doses, Morning and early afternoon, With a choline source
Piracetam powder or capsules
2-4 weeks
30-60 minutes
2-4 weeks
During use
2-4 weeks
1-2 weeks
Ongoing
First few days
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=289
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Piracetam for reducing the incidence of painful sickle cell disease crises
The Cochrane database of systematic reviews (2016) · Meta analysis · n=169
Although there was no significant difference between the piracetam and placebo periods for the number of days of hospitalisation (P = 0.87) in one trial, inconsistencies in the criteria necessary for hospitalisation during sickle crises did not permit accurate conclusions to be drawn.
Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2023) · Meta analysis · n=243
Compared with placebo, high-dose oxytocin (72 international units) was associated with the greatest improvement in patients' neuropsychiatric symptoms (SMD = -1.17, 95% CIs = -2.25 to -0.08, z = -2.10, p = 0.035).
Based on meta-analysis showing MMSE improvement (WMD: 2.27) in dementia populations. Evidence primarily from dementia patients, limited data in healthy individuals. Quality concerns noted in systematic reviews regarding study methodology.
Based on meta-analysis of 1002 stroke patients, but showed non-significant increase in death at one month. Evidence is limited and mixed. Conservative effectiveness estimates due to safety concerns.
AI-estimated from published studies. Interpret as directional guidance.
Huperzine A has a higher evidence score (6/10 vs 4.5/10) and wins in 2 of 3 categories.
For sharpen focus, Huperzine A has a higher relevance score (80 vs 75).
No known interactions between Huperzine A and Piracetam have been documented in our database. However, always consult a healthcare provider before combining supplements.